, Tracking Stock Market Picks
Enter Symbol:
ImmunoCellular Therapeutics Ltd (IMUC) [hlAlert]

3 Months Gains
down 83.12 %

ImmunoCellular Therapeutics Ltd (IMUC) rated Buy with price target $5 by Dawson James

Posted on: Tuesday,  Mar 22, 2011  9:25 AM ET by Dawson James

ImmunoCellular Therapeutics Ltd (IMUC)
rated Buy with price target $5 by Dawson James.

ImmunoCellular Therapeutics, Ltd. is a development stage company that is seeking to develop and commercialize therapeutics to fight cancer using the immune system. The Company?s product candidate portfolio includes peptide based cellular immunotherapies targeting cancer stem cells, cellular immunotherapies targeting cancer antigens and monoclonal antibodies to diagnose and treat different cancers. As of December 31, 2008, the products under development include ICT-121, ICT-107, ICT-109, ICT-037, ICT-69 and ICT-Diagnostic-SCLC. In February 2008, the Company acquired certain monoclonal antibody related technology owned by Molecular Discoveries LLC (Molecular Discoveries).

Dawson James Securities is a full service investment firm with deep expertise in healthcare, biotechnology and technology with a staff of over 50 investment professionals ensures our clients stay ahead of the constant changes in the healthcare capital markets. From our widely-respected institutional research, investment banking and high net worth services to our personalized attention for individual accounts, we provide quality service for our clients. We take pride in the quality and depth of our professionals and encourage you to contact us so we can begin serving your financial needs today.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/22/2011 9:25 AM Buy
2.37 5.00
as of 12/30/2011
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy